Greffex is working on universal vaccines with the aim to provide world-wide protection
A vaccine solution for Ebola that delivers exactly what is needed quickly IS available. Greffex offered two additional components to its vaccine solution.
Greffex can deliver a testable Ebola vaccine candidate in one month from start date.
The GREFLU/VIE™ is being developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). Influenza vaccine manufacturing and clinical testing schemes were discussed with the Food and Drug Administration of the USA. In parallel, Greffex has been working on a universal influenza vaccine with the aim to provide protection prior to the emergence of a new influenza strain.
Greffex has produced the anthrax vaccine GREANX™ using its GREVAX™ platform. GREANX has been undergoing initial preclinical testing. This work is being performed in collaboration with the US Army Medical Research Institute for Infectious Diseases (USAMRIID).
Greffex has produced the Dengue vaccine GREDEN/V1.4 using its GREVAX™ platform. GREDEN/V1.4 has been undergoing initial preclinical testing. This work is being performed in collaboration with the with the National Institute of Allergy and Infectious Diseases (NIAID).
The different influenza variants are identified and a corresponding seasonal vaccine is produced and distributed in the North. This strategy has been successful for many years. Greffex has exploited the flexibility of our GREVAX™ Universal Platform to produce several vaccine constructs, such as a Swine Influenza GREFLU/CAL.
Greffex is presenting today, about one month after the identification of the H7N9 influenza, a completed GREVAXTM H7N9 vaccine construct. This H7N9 vaccine candidate is ready for production and testing.
Greffex has developed a MERS vaccine just four weeks after it became obvious that MERS-CoV had moved to the WHO’s “alert phase.
Predicting the composition of newly emerging influenza strains is close to impossible. Therefore an urgent need exists for influenza vaccines that are effective against many different strains. As Greffex’s GREVAX™ Universal Platform is highly versatile and very fast, the company has been developing broadly reactive (“universal”) influenza vaccines that provide, if not full, at least base protection against the most dangerous influenza strains. A highly specific GREVAX™ vaccine can then be delivered in a few weeks.
More Information can be found here: